Novo Nordisk fell 8% in early trading
2025-04-17 21:38:49

Novo Nordisk fell 8% in early trading after its weight loss drug competitor Eli Lilly achieved positive results in a Phase 3 trial of an oral weight loss drug.
Email Subscription
Newsletters and emails are now available! Delivered on time, every weekday, to keep you up to date with North American business news.
ASIA TECH WIRE

Grasp technology trends

Download